Verucerfont

Drug Profile

Verucerfont

Alternative Names: 561679; CRF1-antagonist - GSK/Neurocrine; GSK-561679; NBI-77860

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurocrine Biosciences
  • Developer GlaxoSmithKline; Neurocrine Biosciences
  • Class Antidepressants; Anxiolytics; Azabicyclo compounds; Oxadiazoles; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholism; Congenital adrenal hyperplasia; Post-traumatic stress disorders
  • No development reported Major depressive disorder; Social phobia
  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Jun 2015 Neurocrine Bioscience suspends a phase I/II trial in Congenital adrenal hyperplasia (In adolescents) in USA prior to enrolment
  • 09 Feb 2015 Neurocrine Biosciences has patent protection for verucerfont in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top